Is a severe preoperative condition a contraindication for aortic valve-sparing reimplantation in type A aortic dissection?

J Cardiovasc Surg (Torino). 2024 Feb;65(1):69-75. doi: 10.23736/S0021-9509.24.12638-9. Epub 2024 Feb 1.

Abstract

Background: Type A aortic dissection (TAAD) surgical management is still under debate. The purpose of this study was to demonstrate the feasibility and safety of the aortic valve-sparing root reconstruction (AVSR) procedure in 92 consecutive patients operated for TAAD, even when preoperative condition was severe (malperfusion, shock or both).

Methods: Our hospital database was reviewed to identify all patients who underwent an AVSR procedure for TAAD over 14 years. From May 2000 to June 2014, 92 consecutive patients were studied regarding to their preoperative condition.

Results: Age (61±13 years) and logistic Euroscore (23.4±15.3%) as well as cross-clamping (113±39 min), cardiopulmonary bypass (142±49 min) and circulatory arrest (22±13 min) times were collected. Hospital mortality was 16.3%. Mean follow-up was complete for a mean period of 27.6 months. One patient had early reoperation for aortic insufficiency. Actuarial survival at 1 year was 82.5%. The analysis of each group showed comparable mortality and morbidity in between patients.

Conclusions: Based upon our experience in the management of TAAD, a reimplantation procedure could be performed regardless preoperative malperfusion or shock, with an acceptable postoperative over mortality or morbidity. A word of caution should be brought to patients over 70 years old.

MeSH terms

  • Aged
  • Aortic Aneurysm* / diagnostic imaging
  • Aortic Aneurysm* / surgery
  • Aortic Dissection* / diagnostic imaging
  • Aortic Dissection* / surgery
  • Aortic Valve / diagnostic imaging
  • Aortic Valve / surgery
  • Aortic Valve Insufficiency* / diagnostic imaging
  • Aortic Valve Insufficiency* / surgery
  • Azides*
  • Contraindications
  • Deoxyglucose / analogs & derivatives*
  • Humans
  • Middle Aged
  • Reoperation
  • Replantation / adverse effects
  • Retrospective Studies
  • Treatment Outcome

Substances

  • 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxyglucopyranose
  • Azides
  • Deoxyglucose